TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB40573

Peptide_Name

AP AP(O)

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF pep-lab

Sequence_Type

standard

Has_Modification No

Description A 25-aa standard natural anticancer peptide sequence curated from ACP740 _ACP240, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.

Sequence

ACDCRGDCFCGGGGIVRRADRAAVP

FASTA

>TPDB40573|Anticancer|length=25
ACDCRGDCFCGGGGIVRRADRAAVP

Formula C100H165N37O32S4

Absent Amino Acids NEQHLKMSTWY

Common Amino Acids G

Mass 2525.88

PI 7.84

Basic Residues 4

Acidic Residues 3

Hydrophobic Residues 8

Net Charge +1

Boman Index 4.49

Hydrophobicity 0.032

Aliphatic Index 54.80

Half Life

Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 250

Absorbance 280nm 9.90

Polar Residues 4

number

4

A

4

R

0

N

3

D

4

C

0

E

0

Q

5

G

0

H

1

I

0

L

0

K

0

M

1

F

1

P

0

S

0

T

0

W

0

Y

2

V

Amino Acid Distribution

A: 4 R: 4 N: 0 D: 3 C: 4 E: 0 Q: 0 G: 5 H: 0 I: 1 L: 0 K: 0 M: 0 F: 1 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 2

Length

25

Formula

C100H165N37O32S4

Mass

2525.88

PI

7.84

Net Charge

+1

Boman Index

4.49

Hydrophobicity

0.032

C_terminal_Modification

Free

Chirality

L

Linear_or_Cyclic

Linear Cyclic(C2-C10,C

N_terminal_Modification

Free

Nature

Antitumor

Origin

Endostatin derived synthetic peptide

Evidence 1 Activity

Activity

Activity Raw

50% inhibition at 2.5µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Tumor

Cell Line BAE

Tissue Affected Not Available

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2010

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Raw

40% inhibition at 5µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Tumor

Cell Line BAE

Tissue Affected Not Available

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2010

Evidence 3 Activity

Activity

Activity Raw

75% inhibition at 10µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Tumor

Cell Line BAE

Tissue Affected Not Available

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2010

Evidence 4 Activity

Activity

Activity Raw

40% inhibition at 2.5µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Tumor

Cell Line BAE

Tissue Affected Not Available

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2010

Evidence 5 Activity

Activity

Activity Raw

42% inhibition at 5µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Tumor

Cell Line BAE

Tissue Affected Not Available

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2010

Evidence 6 Activity

Activity

Activity Raw

52% inhibition at 10µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Tumor

Cell Line BAE

Tissue Affected Not Available

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2010